Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2021

View Archived Issues

Neuron-specific delivery platform based on a chimeric toxin for botulism postexposure treatment

Incyte initiates phase I/II study of INCB-000928 in patients with anemia due to MF

Phase I trial investigates NNC0361-0041 for type 1 diabetes

Study links ALS gene to tumor suppressor, transcription changes

Membrane rupture is active event

Xarelto approved in Japan to treat children with VTE and to prevent VTE recurrence

Exelixis initiates first-in-human study of XL-102 in advanced or metastatic solid tumors

Bavencio approved in Europe as first-line maintenance for urothelial carcinoma

UCB patents dopamine D1 receptor PAMs

Roche synthesizes MGL inhibitors

Progen presents new fusion proteins for autoimmune diseases

Chinese researchers present CAR T-cell therapy for cancer

AR agonist-based strategy proposed for ER+ breast cancer

Zymso approved in Japan for interstitial cystitis

Merck & Co. discontinues development of V-590 and V-591 vaccine candidates

New NFE2L2 activators patented by Senju Pharmaceutical

Dosing begins in phase II study of MVC-COV-1901 vaccine in Taiwan

StemVacs induces regression of glioma, lung and colorectal cancer tumors in vivo

Ivermectin use tied to lower mortality in patients with COVID-19

5-HT2B as a novel therapeutic target to improve microstructural remodeling post-MI

Dosing begins in phase I study of TJ-210 in advanced solid tumors

Rinvoq approved in E.U. for psoriatic arthritis and ankylosing spondylitis

Curadigm's Nanoprimer-based project selected for Sanofi iTech Awards program

One-year data from SPIRIT Extension study of relugolix combination therapy in endometriosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...